Combination treatment with a GLP-1 agonist and thiazolidinedione in type 2 diabetes was tied to a significantly lower risk of ...

Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development of VX-264.

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex halts VX-264 diabetes cell therapy due to poor efficacy in Phase 1/2 study, but continues Phase 3 trial of zimislecel ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Vertex Pharmaceuticals Incorporated today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...

Cadillac's new small EV comes with 300 miles of range, Super Cruise, all-wheel-drive and a $7,500 EV tax credit. What's not ...